AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15388005
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (MVP chemotherapy only)
Trial: 15388005
Drug: Pre-treatment arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment arm (previously treated with chemotherapy)
Trial: 11399102
Drug: Hyaluronan (Hyalgan),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan (Hyalgan), 20 mg/2 ml once a week for 5 weeks
Trial: 11399102
Drug: Methylprednisolone (Depo‐Medrol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (Depo‐Medrol, 40 mg/1 ml once a week for 3 weeks)
Trial: 9416723
Drug: Aprotinin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (total dose, 6 x 10(6) kallikrein inactivator units)
Trial: 9416723
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (total dose, 270 mg/kg)
Trial: 8495761
Drug: Superovulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superovulation with adjunctive leuprolide acetate (LA) therapy
Trial: 8495761
Drug: Superovulation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Superovulation without adjunctive leuprolide acetate (LA) therapy
Trial: 3122065
Drug: Exercise 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise 3 times weekly for 1 month
Trial: 3122065
Drug: Exercise 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise 7 times weekly for 1 month
Trial: 3122065
Drug: Exercise 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise 3 times weekly for 1 year
Trial: 3122065
Drug: Exercise 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise 3 times weekly after cessation of long-term drug therapy
Trial: 29976277
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg once daily for 1 week followed by 20 mg once daily (intensive treatment group, IT group, n=49)
Trial: 29976277
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg once daily (standard treatment group, ST group, n=54)
Trial: 29976277
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg once daily for 1 week followed by 20 mg once daily (intensive treatment group, IT group)
Trial: 29976277
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg once daily (standard treatment group, ST group)
Trial: 26988432
Drug: 14% Plai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14% Plai cream
Trial: 26988432
Drug: 7% Plai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% Plai cream
Trial: 12136225
Drug: Informational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Informational intervention (specific, objective information about radiation treatments)
Trial: 2683543
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral blockade with bupivacaine 0.5% (15 ml followed by 5 ml/h)
Trial: 2683543
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural blockade with bupivacaine 7 ml 0.5% + morphine 2 mg followed by 5 ml/h + 0.2 mg/h
Trial: 29785889
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation at 0.5 g/kg feed
Trial: 29785889
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation at 1.0 g/kg feed
Trial: 29785889
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation at 2.0 g/kg feed
Trial: 24119149
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (50,000 IU) administered orally every week for 8 weeks
Trial: 24119149
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally every week for 8 weeks
Trial: 22026529
Drug: Genuine auricular
RxNorm normalized name: Genuine First Aid - Auto First Aid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genuine auricular therapy
Trial: 22026529
Drug: Sham auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham auricular therapy (control)
Trial: 22026529
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (genuine auricular therapy and sham)
Trial: 19187286
Drug: Albiglutide (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (0.25 + 1 mg, 3 + 6 mg, 16 + 24 mg, 48 + 60 mg, 80 + 104 mg)
Trial: 16280089
Drug: NSAIDs and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs and/or SMT in addition to general practitioner advice and paracetamol
Trial: 10326923
Drug: Gel cushion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel cushion (tilted position)
Trial: 10326923
Drug: Gel cushion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel cushion (upright position)
Trial: 8566580
Drug: Intracolonic injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracolonic injection of glycerol
Trial: 8566580
Drug: Intrarectal injection
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal injection of glycerol
Trial: 8566580
Drug: Lidocaine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (administered prior to glycerol injection)
Trial: 8566580
Drug: Paraffin oil
RxNorm normalized name: Paraffin Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin oil (control for glycerol injection)
Trial: 8566580
Drug: Octreotide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide and granisetron (drugs acting on visceral afferent pathways)
Trial: 8566580
Drug: Phloroglucinol (spasmolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol (spasmolytic drug)
Trial: 7184471
Drug: Topical tuberculin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tuberculin jelly (14 patients)
Trial: 17572422
Drug: Micronized 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized 17beta‐estradiol 1 mg plus dydrogesterone 10 mg sequential added (LD‐HT; group A)
Trial: 17572422
Drug: Dydrogesterone 10
RxNorm normalized name: dydrogesterone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 10 mg from day 15 to 28 (group B)
Trial: 8824737
Drug: Other Ayurvedic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Ayurvedic formulations
Trial: 30686952
Drug: GC1107 (adult
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1107 (adult tetanus diphtheria vaccine)
Trial: 30686952
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (Td vaccine)
Trial: 25608632
Drug: Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen Axetil (FA) with fentanyl in postoperative controlled intravenous analgesia (PCIA)
Trial: 23592107
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave + placebo infusion
Trial: 19419845
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Pindolol
Trial: 16684688
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (Ventoline Diskhaler) 200 microg three times a day
Trial: 11736858
Drug: (+)-chlorpheniramine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-chlorpheniramine 6 mg
Trial: 9246150
Drug: Single i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. dolasetron dose (0.6 mg/kg) before cisplatin
Trial: 9246150
Drug: Multiple i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple i.v. dose regimen (0.6 mg/kg x 3) given before and after cisplatin
Trial: 31160146
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day for four days)
Trial: 19696637
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal (prednisone) for 3 months
Trial: 19696637
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (prednisone, cyclosporine, and mycophenolate)
Trial: 8259034
Drug: Total therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total therapeutic paracentesis (TTP) plus i.v. albumin (5 g/l of fluid)
Trial: 3519644
Drug: Bromocriptine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (1.25 mg twice daily, increased to 2.5 mg twice daily if no improvement)
Trial: 28688525
Drug: FDG-guided dose-escalation
RxNorm normalized name: (18F)-FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG-guided dose-escalation (mean doses of 95Gy for tumour and 74Gy for lymph nodes)
Trial: 28688525
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (66Gy/33F plans)
Trial: 25714724
Drug: A standardized
RxNorm normalized name: Echinacea 400 MG Oral Capsule [ECHINACEA STANDARDIZED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized extract from Ageratina pichinchensis (5 %, cream formulation)
Trial: 22836585
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 70 mg/week in addition to TPTD
Trial: 22836585
Drug: Raloxifene (RAL)
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene (RAL) 60 mg/d in addition to TPTD
Trial: 22836585
Drug: TPTD monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPTD monotherapy (no additional medication)
Trial: 16464979
Drug: Subacromial fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subacromial fentanyl 4 microg ml(‐1) (Group F)
Trial: 16464979
Drug: i.v. fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. fentanyl 4 microg ml(‐1) (Group C)
Trial: 15142198
Drug: Asacol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol (800 mg)
Trial: 15142198
Drug: Balsalazide (2250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide (2250 mg)
Trial: 9762783
Drug: formoterol dry
RxNorm normalized name: aclidinium / formoterol Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol dry powder 24 microg twice daily (08:00 and 20:00 h)
Trial: 9762783
Drug: formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol 24 microg once daily (20:00 h)
Trial: 28349504
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intravitreal bevacizumab (IVB) injection
Trial: 28349504
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1.25 mg IVB and 1 mg intravitreal triamcinolone (IVT)
Trial: 28349504
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1.25 mg IVB and 1 mg IVT
Trial: 21312288
Drug: Vehicle plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle plus 75 g of glucose
Trial: 21312288
Drug: Vehicle plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle plus 75 mg of caffeine
Trial: 21312288
Drug: Vehicle plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle plus 75 g of glucose and 75 mg of caffeine
Trial: 21312288
Drug: Vehicle (water,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (water, 150 ml)
Trial: 18221474
Drug: Simultaneous intramuscular
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous intramuscular influenza and pneumococcal heptavalent conjugate vaccinations (IV + PV)
Trial: 16773418
Drug: Ayurvedic polyherbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic polyherbal preparation 'Shathavaryadi Yoga (NS001)'
Trial: 12742282
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg/day, n = 15)
Trial: 12742282
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/day, n = 15)
Trial: 12742282
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (Atorvastatin and Simvastatin)
Trial: 8827017
Drug: Prechemotherapy G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prechemotherapy G‐CSF (administered subcutaneously twice per day for 5 days at a dose of 5 micrograms/kg)
Trial: 8827017
Drug: Postchemotherapy G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postchemotherapy G‐CSF (administered subcutaneously once per day for 7 days at a dose of 5 micrograms/kg)
Trial: 8827017
Drug: Prechemotherapy G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prechemotherapy G‐CSF
Trial: 8827017
Drug: Postchemotherapy G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postchemotherapy G‐CSF
Trial: 1462413
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 g at bedtime
Trial: 3892050
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin immunotherapy
Trial: 3892050
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin immunotherapy with positive skin test conversion
Trial: 3892050
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin immunotherapy with negative skin test
Trial: 3892050
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin immunotherapy with previously positive skin test
Trial: 3892050
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin immunotherapy in high-risk patients
Trial: 30920684
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive processing therapy
Trial: 30920684
Drug: Group present-centered
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group present-centered therapy
Trial: 29081351
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure (PE) plus pill placebo
Trial: 29081351
Drug: Sertraline (SERT)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (SERT) plus Enhanced Medication Management (EMM)
Trial: 29081351
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (PE/SERT)
Trial: 23700945
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous omega-3 PUFAs (Omegaven 10%) infusion
Trial: 23700945
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution infusion (control group)
Trial: 12973173
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution (30% glucose in water with insulin 50 U/L, and KCl 40 mM/L) at 1.5 mL/kg/hr for 24 hrs
Trial: 10696980
Drug: No interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No interferon therapy
Trial: 23511293
Drug: Gabapentin (dosage:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (dosage: 300 mg TID, 600 mg TID, 800 mg TID, 1200 mg TID)
Trial: 12426230
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg loading dose and 10 mg/hour until Day 3)
Trial: 31405764
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily before surgery
Trial: 29799960
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Trial: 28057360
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47)
Trial: 26174611
Drug: AZD0837 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0837 (oral direct thrombin inhibitor)
Trial: 23428337
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 (2.5, 10, or 60 mg)
Trial: 23428337
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 (30 mg)
Trial: 21526919
Drug: Routine upfront
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine upfront abciximab administration (bolus followed by 12-hour infusion)
Trial: 21526919
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (selective abciximab use during intervention)
Trial: 21526919
Drug: Routine upfront
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine upfront abciximab administration
Trial: 16243440
Drug: Intravenous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amifostine 300 mg/m2
Trial: 12527537
Drug: Standard Cognitive-Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive-Behavior Therapy (CBT)
Trial: 12527537
Drug: Enhanced Cognitive-Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Cognitive-Behavior Therapy (ECBT)
Trial: 10638560
Drug: Pantoprazole (PANT)
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole (PANT) 40 mg
Trial: 10638560
Drug: Ranitidine (RAN)
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine (RAN) 300 mg
Trial: 27894358
Drug: Daily online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily online math training (control condition)
Trial: 21422713
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 IU/d) and Vitamin C (500 mg/d) supplementation
Trial: 10539870
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d Zithromax for 3 days then 600 mg/wk for 11 additional weeks
Trial: 2317751
Drug: Simultaneous combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous combined technique therapy (SIM)
Trial: 2317751
Drug: Sequential combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combined technique therapy (SEQ)
Trial: 30526388
Drug: Acacia bark
RxNorm normalized name: ROBINIA PSEUDOACACIA BARK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acacia bark extract tablets
Trial: 22622962
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid (choline fenofibrate) 135 mg once daily
Trial: 22622962
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus atorvastatin treatment
Trial: 25369725
Drug: Cognitive-behavioral therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapies
Trial: 9285657
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (amiodarone or sotalol)
Trial: 3453292
Drug: Sotalol hydrochloride
RxNorm normalized name: Sotalol Hydrochloride
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sotalol hydrochloride 80 mg and hydrochlorothiazide 12.5 mg
Trial: 30144304
Drug: Budesonide (BD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BD) 256 μg
Trial: 30144304
Drug: Montelukast (MNT)
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast (MNT) 10 mg
Trial: 30144304
Drug: Half-dose Budesonide
RxNorm normalized name: budesonide Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose Budesonide (hBD) 128 μg + Montelukast (MNT)